ModernThe startup, which goals to increase how long people can live a healthy life, genetically programming their cells, collected a B -series with a value of $ 130 million led by Kleiner Perkins.
New investors of Nat Friedman, Daniel Gross and Khosla Ventures also invested, as did the returning founding fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison and others. Collecting funds appears two years after the company collected a series of $ 40 million A.
Founded over 4 years ago by Coinbase Brian Armstrong (pictured above), former GV Blake Byers partner and a stem cell professor Jacob Kimmel, Newlimit claims that he has made significant progress in the development of treatment that may restore youthful features to aging cells.
Kimmel told Techcrunch that the company has discovered three prototype drugs that reprogram the liver cells. He said that Newlimit laboratory experiments show that this rejuvenation can restore cells and alcohol processing.
The company measures its progress, contrasting how the cells from a younger person and an elderly person react to substances. Kimmel said that an older liver cell that has passed through epigenetic reprogramming Newlimit behaves more like a younger cell.
Regardless of the early results, Newlimit is still a few years from the start of trials for people.
In the meantime, the company wants to proceed to develop recent anti -aging drugs using the AI model, and then test the most promising of these machine -generated drugs in its laboratory. “The AI model allows us to do it, launch all these experiments in the simulation, and then observe the most promising subset,” said Kimmel, adding that the data points from the experiment are then used to persuade the AI model in a process referred to as “Laboratory in a loop”.
TechCrunch event
Berkeley, California
|.
June 5
Book now
Other noteworthy biotechnological startups developing drugs that are aimed at increasing life, include retro biosciences, which two years ago raised $ 180 million from the general director OPENAI, and apparently raises a series A series value $ 1 billion; and Altos Labs, which fired with $ 3 billion in 2022 and is supported by Jeff Bezos.